Search for: "Impax Laboratories, Inc. v. Federal Trade Commission" Results 1 - 3 of 3
Sort by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
18 Apr 2016, 12:49 pm by Gene Quinn
The FTC’s complaint alleges that Endo engaged in a pay for delay scheme by paying the first generic companies that filed for FDA approval – Impax Laboratories, Inc. and Watson Laboratories, Inc. [read post]
11 Apr 2016, 2:32 pm by Robert Reznick
  The FTC’s complaint attacks two such settlements that Endo Pharmaceuticals Inc. and the Japan-based patent holder for one of the relevant patents reached with generic manufacturers Watson Laboratories (and Watson’s current owner, Allergan plc) and Impax Laboratories, to settle Hatch-Waxman litigation involving Endo’s two most important products—the pain relievers Opana ER® and Lidoderm®.[2]  The FTC’s complaint,… [read post]